Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD34(+) or CD34(-): which is the more primitive?

M Engelhardt1, M Lübbert, Y Guo

  • 1University of Freiburg Medical Center, Department of Hematology/Oncology, Freiburg, Germany.

Leukemia
|August 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The spatio-functional cortical representation of muscles innervated by the accessory nerve using nTMS.

Clinical neurophysiology practice·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Long-term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: A case series.

British journal of haematology·2024
Same author

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

Leukemia·2024
Same author

Effects of foam rolling on vastus intermedius and lateralis microvascular blood flow.

Journal of bodywork and movement therapies·2023
Same author

Training in vascular trauma surgery for non-vascular surgeons: Vascular trauma surgery skills course.

European surgery : ACA : Acta chirurgica Austriaca·2023
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
See all related articles

Hematopoietic stem cells (HSCs) are crucial for blood cell production. Recent research reveals that both CD34-positive and CD34-negative HSCs exist, challenging previous assumptions about HSC identification and function.

Area of Science:

  • Hematology
  • Stem Cell Biology
  • Immunology

Background:

  • Hematopoietic stem cells (HSCs) are vital for lifelong blood cell production.
  • HSCs are a small cell population responsible for self-renewal and differentiation.
  • CD34 has been a primary marker for identifying and isolating HSCs for clinical applications.

Purpose of the Study:

  • To review recent findings on CD34-positive and CD34-negative HSCs.
  • To examine the characteristics and differences between CD34(+) and CD34(-) HSCs.
  • To discuss the implications of CD34(-) HSCs for stem cell biology and therapy.

Main Methods:

  • Review of recent murine and human studies on HSC characterization.
  • Analysis of data on CD34(+) and CD34(-) HSC populations.

Related Experiment Videos

  • Examination of the functional properties and potential interactions of different HSC subsets.

    • Main Results:

    • Evidence suggests the existence of functional HSCs that are CD34-negative.
    • CD34(-) HSCs exhibit engraftment potential and distinct characteristics.
    • These findings challenge the exclusive reliance on CD34 as an HSC marker.

    Conclusions:

    • The identification and isolation of primitive HSCs require a broader perspective beyond CD34.
    • Both CD34(+) and CD34(-) HSC populations may play roles in hematopoiesis.
    • Further research is needed to understand the interplay between CD34(+) and CD34(-) HSCs for therapeutic advancements.